key: cord-0991185-e4ph3dc4 authors: Patel, Rachna; Czuprynska, Julia; Roberts, Lara N.; Vadher, Bipin; Rea, Catherine; Patel, Raj; Gee, Emma; Saul, Gabrielle; Coles, Evelyn; Brown, Alison; Byrne, Rosalind; Speed, Vicky; Patel, Jignesh P.; Arya, Roopen title: Switching warfarin patients to a direct oral anticoagulant during the Coronavirus Disease-19 pandemic date: 2020-11-07 journal: Thromb Res DOI: 10.1016/j.thromres.2020.11.004 sha: 136d10ba2db832b70e2f9c691ee3d781e57f09e4 doc_id: 991185 cord_uid: e4ph3dc4 nan Over the initial 8 week period, 186 patients were switched from VKA to a DOAC virtually, of which 133 (71.5%) were surveyed for their feedback at one month (74 at the PRUH and 59 at DH). This cohort of patients had a mean age 79 (sd 1.88) years and a mean time in therapeutic range (TTR) of Suitable patients, who could be switched to a DOAC were proactively identified from DAWN® (exclusion criteria for DOACs applied [3] ), prioritising patients with a low time in therapeutic range (TTR) <65% and those requiring home testing through district nurse sampling. For this initiative, we included patients who had previously been asked about a switch to a DOAC and had previously declined. Switching was undertaken by nurses, doctors and pharmacists within our anticoagulation team. Patient's past medical history and medication history were obtained using local care summary records to assess suitablity to switch to a DOAC Patients were telephoned to discuss if they might be interested in a switch. Medical and medication history confirmed with patient. If patients were agreeable, a suitable DOAC was chosen based on their individual circumstances, latest blood results and in line with local prescribing policies. [4] [5] Patient Counselling and medication supply During the pandemic, our pharmacy departments initiated a delivery service of urgent medications to patients' homes. Patients (and relatives, where appropriate) were fully counselled over the phone on the chosen DOAC therapy. A patient information leaflet and DOAC alert card were delivered with the medication. Patients were advised that once their DOAC had been delivered, they should stop warfarin for 2 days and then start the DOAC. This only differed in cases, where a recent INR had been available. At the point of intitation, all patients were safety netted with the anticoagulation clinic number and advised to contact the clinic with any problems. Selected patients were scheduled a follow up telephone call to ensure the DOAC was well tolerated. GPs were asked to take over prescribing after 3 months, as per the local South East London policy. One month after switching, patients received a phone call from a member of the team who was not involved in the switching process to answer a series of questions to capture their experience of the virtual switching process. J o u r n a l P r e -p r o o f Journal Pre-proof 66%. The majority of patients (n=108, 81%) were prescribed anticoagulation for non-valvular atrial fibrillation, 20 patients (15%)for the secondary prevention of VTE and 5 patients (4%) had another indication for anticoagulation. Edoxaban was the most frequently prescribed DOAC (n=85, 65%), followed by apixaban (n=38, 29%) and rivaroxaban (n=10, 7%).Side effects to DOACs were reported by 12.7% (17/133)of patients, with dizziness, itching and headaches most commonly reported (Table 1 ). At 1 month follow up, 96% of patients continued on their initially prescribed DOAC as side effects were minor/tolerable, with 90% of patients reporting they were very satisfied/satisfied with their DOAC. Four patients (3%) switched back to warfarin and 1 patient (0.8%) switched to an alternative DOAC due to side effects. Most patients rated the quality of their consultation over the phone as excellent/very good (80%) and just over half (52%) expressed a preference for virtual consultations versus face-to-face, mainly due to the convenience this offered and reluctance to attend a hospital setting during the pandemic. 15 patients (12%) did state they would have preferred a face-to-face consultation and the remainder (35%) did not have a preference for either. Recent correspondence in the British Medical Journal [7] [8] from primary care clinicians demonstrate that although telephone consultations have a role in service delivery, a wholesale change is not appropriate for all, particularly those on the wrong side of the digital divide. Long-term adherence to DOAC therapy has been reported to be sub-optimal; with a reported 65.9% adherence at one year [9] Patients' adherence beliefs are affected by numerous factors, which in part may be influenced by the clinician-patient interaction. Outside of a pandemic setting, our own group have reported on short term changes in beliefs (medication: overuse, harm, necessity and concerns) and quality of life in 142 poorly controlled patients, switched from warfarin to a DOAC. [10] Our results demonstrate that patients experience significant early changes in beliefs and quality of life following a switch from warfarin to a DOAC, representing a shift towards belief patterns predictive of improved adherence. It is important to establish if these improvements are also seen when the switch process occurs through the telephone and what long term adherence rates are. As most patients (>90%) remain on a DOAC, we regard this switching initiative during the pandemic a success, overall. We hope by sharing our experiences, this will benefit other centres, given the wave suggests that telephone switching of warfarin patients to a DOAC is safe and most patients find such an initiative favourable. Medicines and Healthcare products Regulatory Agency (MHRA). Warfarin and other oral anticoagulants-monitoring of patients during the COVID-19 pandemic A perfect storm: Root cause analysis of supratherapeutic anticoagulation with vitamin K antagonists during the COVID-19 pandemic Clinical guide for the management of anticoagulant services during the coronavirus pandemic South East London Area prescribing committee (2020) Initiation of anticoagulation in NVAF Guidance for the safe switching of warfarin to direct oral anticoagulants (DOACs) for patients with non-valvular AF and venous thromboembolism (DVT/PE) during the coronavirus pandemic March Guidance for the safe switching of warfarin to direct oral anticoagulants (DOACs) for patients with non-valvular AF and venous thromboembolism (DVT / PE) during the coronavirus pandemic Definition of clinically relevant nonmajor bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH Teleconsultations compromise patient safety and professional satisfaction. bmj Telemedicine: unseen unknowns. bmj Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study Early changes in medication beliefs, illness perceptions and anticoagulation related quality of life in patients poorly controlled on vitamin-K antagonists switched to a direct oral anticoagulant -early results from the Switching study